SG11201803934YA - Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies - Google Patents

Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies

Info

Publication number
SG11201803934YA
SG11201803934YA SG11201803934YA SG11201803934YA SG11201803934YA SG 11201803934Y A SG11201803934Y A SG 11201803934YA SG 11201803934Y A SG11201803934Y A SG 11201803934YA SG 11201803934Y A SG11201803934Y A SG 11201803934YA SG 11201803934Y A SG11201803934Y A SG 11201803934YA
Authority
SG
Singapore
Prior art keywords
international
rule
compositions
expression
biologically active
Prior art date
Application number
SG11201803934YA
Inventor
Dimki S Patel
Amit N Patel
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of SG11201803934YA publication Critical patent/SG11201803934YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - Organization International Bureau irestYlid (43) International Publication Date ..... ..sr ,„,„01 18 May 2017 (18.05.2017) WIPO I PCT (10) WO International Publication Number 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/083750 Al (51) International Patent Classification: KW, C07K 14/52 (2006.01) A61K 48/00 (2006.01) MG, A61K 38/16 (2006.01) C12N 15/62 (2006.01) OM, SC, (21) International Application Number: TN, PCT/US2016/061668 ZW. (22) International Filing Date: (84) Designated 11 November 2016 (11.11.2016) kind (25) Filing Language: English GM, TZ, (26) Publication Language: English TJ, (30) Priority Data: DK, 62/254,139 11 November 2015 (11.11.2015) US LV, SM, KZ, LA, LC, LK, LR, LS, MK, MN, MW, MX, MY, PA, PE, PG, PH, PL, PT, SD, SE, SG, SK, SL, SM, TR, TT, TZ, UA, UG, States (unless otherwise of regional protection available): KE, LR, LS, MW, MZ, UG, ZM, ZW), Eurasian (AM, TM), European (AL, AT, EE, ES, FI, FR, GB, GR, MC, MK, MT, NL, NO, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, LU, LY, MA, MD, ME, MZ, NA, NG, NI, NO, NZ, QA, RO, RS, RU, RW, SA, ST, SV, SY, TH, TJ, TM, US, UZ, VC, VN, ZA, ZM, indicated, for every ARIPO (BW, GH, NA, RW, SD, SL, ST, SZ, AZ, BY, KG, KZ, RU, BE, BG, CH, CY, CZ, DE, HR, HU, IE, IS, IT, LT, LU, PL, PT, RO, RS, SE, SI, SK, (71) Applicant: INTREXON CORPORATION [US/US]; GW, KM, ML, MR, NE, SN, TD, 20358 Seneca Meadows Pkwy, Germantown, Maryland 20876 (US). Declarations (72) Inventors: PATEL, Dimki S ; 20358 Seneca Meadows as under Rule 4.17: to applicant's entitlement to TG). apply for and be granted a Pkwy, Germantown, Maryland 20876 (US). PATEL, Amit patent (Rule 4.17(ii)) N.; 1040 Chartwell Ct., Salt Lake City, Utah 84103 (US). — as earlier application (Rule 4.17(iii)) to the applicant's entitlement to claim the priority of the (74) Agent: GIRINATH, Prashant; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 Published: (US). — with international search report (Art 21(3)) Designated States indicated, (81) (unless otherwise for every _ before the expiration of the time limit for amending the kind of national available): AE, AG, AL, AM, protection claims and to be republished in the event of receipt of AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, amendments (Rule 48.2(h)) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, with sequence listing part of description (Rule 5.2(a)) HN, HR, HU, ID, IL, IN, IR, IS, KE, KG, KN, KP, KR, JP, (54) Title: COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLY- PEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIES ORI ter -2 Car d iac Il .4t C un N en cc o FIG. I IN Il C (57) : The present invention provides compositions and methods useful for treating disorders amenable to therapy via intro - N duction of multigenic expression vectors. More particularly, the invention provides vectors and polynucleotides encoding poly- 0 peptides for treatment of cardiac disorders wherein said polypeptides may comprise a cytokine, a chemokine, and/or an angiogenic ,..I polypeptide, or functional derivatives thereof. Also provided, as compositions of the invention, are linkers useful for connecting and expressing functional (biologically active) polypeptides from single, multigenic-expression constructs.
SG11201803934YA 2015-11-11 2016-11-11 Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies SG11201803934YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254139P 2015-11-11 2015-11-11
PCT/US2016/061668 WO2017083750A1 (en) 2015-11-11 2016-11-11 Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies

Publications (1)

Publication Number Publication Date
SG11201803934YA true SG11201803934YA (en) 2018-06-28

Family

ID=57543150

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803934YA SG11201803934YA (en) 2015-11-11 2016-11-11 Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies

Country Status (14)

Country Link
US (2) US11154622B2 (en)
EP (1) EP3387010A1 (en)
JP (1) JP6976244B2 (en)
KR (1) KR20180069081A (en)
CN (1) CN108713025A (en)
AU (1) AU2016353342B2 (en)
BR (1) BR112018009645A2 (en)
CA (1) CA3004742A1 (en)
HK (1) HK1259137A1 (en)
MA (1) MA43404A (en)
MX (1) MX2018005886A (en)
RU (1) RU2758489C2 (en)
SG (1) SG11201803934YA (en)
WO (1) WO2017083750A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267865B1 (en) 2017-01-10 2024-03-01 Intrexon Corp Modulating expression of polypeptides via new gene switch expression systems
WO2019066548A2 (en) * 2017-09-29 2019-04-04 (주)벳바젠 Pharmaceutical composition for prevention or treatment of heart failure
AU2019231652A1 (en) 2018-03-06 2020-10-01 Precigen, Inc. Hepatitis B vaccines and uses of the same
WO2019218091A1 (en) * 2018-05-18 2019-11-21 UNIVERSITé LAVAL Vectors for dna vaccination
MX2020012649A (en) * 2018-05-25 2021-07-02 The Wistar Inst Tumor-specific neoantigens and methods of using the same.
SG11202103235PA (en) 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
MX2021003744A (en) 2018-10-01 2021-06-23 Adicet Bio Inc Compositions and methods regarding engineered and non-engineered î³î´ -t cells for treatment of solid tumors.
JP2022528197A (en) * 2019-03-29 2022-06-08 アビオメド インコーポレイテッド Systems and methods for reducing left ventricular load in biological or vector gene therapy
US20210290753A1 (en) * 2019-05-21 2021-09-23 UNIVERSITé LAVAL Crimean-congo hemorrhagic fever virus immunogenic compositions
WO2021053222A1 (en) * 2019-09-20 2021-03-25 Ucl Business Ltd Gene therapy composition and treatment of right ventricular arrythmogenic cardiomyopathy
IL300263A (en) * 2020-08-07 2023-03-01 Spacecraft Seven Llc Plakophilin-2 (pkp2) gene therapy using aav vector
US11781156B2 (en) * 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
IL310763A (en) * 2021-08-12 2024-04-01 Univ Temple Retrograde coronary venous or sinus administration of therapeutics
WO2023232984A1 (en) * 2022-06-02 2023-12-07 Patrick Most S100a1 protein for use in treating and preventing infarct extension

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5117057A (en) 1985-10-21 1992-05-26 Rohm And Haas Company Insecticidal N' substituted-N-N'-disubstituted-hydrazines
US4985461A (en) 1985-10-21 1991-01-15 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5225443A (en) 1986-05-01 1993-07-06 Rohm And Haas Company Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
IL100643A (en) 1991-01-25 1996-10-31 Nippon Kayaku Kk Hydrazine derivatives and pesticidal compositions comprising such derivatives as effective component
US5530028A (en) 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
EP1266015B1 (en) 2000-03-22 2006-08-30 RheoGene Holdings Inc. Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
MXPA03007493A (en) 2001-02-20 2004-10-15 Rheogene Holdings Inc Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system.
EP2374891B1 (en) 2001-02-20 2013-05-08 Intrexon Corporation Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system
CA2445796C (en) 2001-02-20 2014-09-16 Rheogene, Inc. Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
JP4994563B2 (en) 2001-02-20 2012-08-08 イントレキソン コーポレーション Novel substitution mutant receptors and their use in nuclear receptor-based inducible gene expression systems
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
JP2005532781A (en) 2001-09-26 2005-11-04 レオジーン・ホールディングス，インコーポレーテッド Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
JP2005507247A (en) 2001-09-26 2005-03-17 レオジーン・ホールディングス，インコーポレーテッド Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
PT2043662E (en) 2006-07-26 2015-11-25 Intrexon Corp Methods and compositions for treating disease
US7719424B2 (en) 2007-01-19 2010-05-18 Igt Table monitoring identification system, wager tagging and felt coordinate mapping
EP3357904B1 (en) 2007-05-29 2022-07-06 Precigen, Inc. Chiral diachylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US20090136465A1 (en) * 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
HUE035406T2 (en) 2007-10-08 2018-05-02 Intrexon Corp Engineered dendritic cells and uses for the treatment of cancer
JP5634272B2 (en) * 2008-03-14 2014-12-03 ヒューマンザイム リミテッド Recombinant production of authentic human protein using human cell expression system
BRPI0920679A2 (en) 2008-10-08 2022-05-17 Intrexon Corp Cells constructed expressing multiple immunomodulators and uses thereof
US20120283315A1 (en) 2009-08-28 2012-11-08 Penn Marc S Sdf-1 delivery for treating ischemic tissue
JP2013527753A (en) 2010-03-23 2013-07-04 イントレキソン コーポレーション Vectors that conditionally express therapeutic proteins, host cells containing the vectors, and uses thereof
JP6189754B2 (en) 2011-03-04 2017-08-30 イントレキソン コーポレーション Vectors that conditionally express proteins
CN104244973B (en) * 2012-11-16 2017-10-20 美国联合生物医学公司 For the urgent vaccine based on synthetic peptide of aftosa (FMD)
WO2014089121A2 (en) * 2012-12-03 2014-06-12 Thomas Ichim Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases
CA2904540A1 (en) 2013-03-15 2014-09-18 The Cleveland Clinic Foundation Retrograde delivery of sdf-1 for treatment of myocardial infarction
WO2016187585A1 (en) 2015-05-20 2016-11-24 Viventia Bio Inc. Deimmunized linker and methods of use
CN105754990A (en) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 Preparation method and application of PD-1/CTLA-4 (programmed death-1/cytotoxic T lymphocyte antigen-4) bispecific antibody

Also Published As

Publication number Publication date
CA3004742A1 (en) 2017-05-18
HK1259137A1 (en) 2019-11-29
AU2016353342B2 (en) 2021-04-01
BR112018009645A2 (en) 2018-11-13
US11154622B2 (en) 2021-10-26
JP2018536405A (en) 2018-12-13
AU2016353342A1 (en) 2018-05-24
US20180360992A1 (en) 2018-12-20
WO2017083750A1 (en) 2017-05-18
RU2018117674A (en) 2019-12-13
MX2018005886A (en) 2018-08-15
US20220072159A1 (en) 2022-03-10
JP6976244B2 (en) 2021-12-08
MA43404A (en) 2018-10-17
EP3387010A1 (en) 2018-10-17
KR20180069081A (en) 2018-06-22
RU2018117674A3 (en) 2020-04-20
RU2758489C2 (en) 2021-10-28
CN108713025A (en) 2018-10-26

Similar Documents

Publication Publication Date Title
SG11201803934YA (en) Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201811432WA (en) Rna for cancer therapy
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201804713VA (en) TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201805784PA (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201803975SA (en) Improved tnf binders
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201906271QA (en) Potent and short promoter for expression of heterologous genes
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same